



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/402,636	04/26/2000	Richard B. Mazess	17620-9277	6232

7590 03/25/2003

Teresa J Welch  
Michael Best & Friedrich  
One South Pinckney Street Suite 700  
PO Box 1806  
Madison, WI 53701-1806

EXAMINER

HUYNH, PHUONG N

ART-UNIT

PAPER NUMBER

1644

DATE MAILED: 03/25/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Interview Summary</b>	Application No.	Applicant(s)
	09/402,636	MASCAX ET AL.
	Examiner "Neon" Phuong Huynh	Art Unit 1644

All participants (applicant, applicant's representative, PTO personnel):

- (1) "Neon" Phuong Huynh. (3) \_\_\_\_\_  
 (2) Gregory Hartwig. (4) \_\_\_\_\_

Date of Interview: 27 February 2003.

Type: a) Telephonic b) Video Conference

c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.

If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: All.

Identification of prior art discussed: \_\_\_\_\_.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.


Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Suggested to Applicant to amend base claim 1 to recite the specific structure for "vitamin D moiety" such as the ones disclosed on page 11-12 of the specification, and to limit the "targeting molecule" as recited in claim 44 to bisphosphonate, DHEA, estrogen tetracycline, calcitonin, osteonectin and osteopontin to overcome the USC 112 1st written description rejection.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.



Examiner's signature, if required